New pill for psoriasis shows promise in early trial
NCT ID NCT05453942
First seen Nov 01, 2025 · Last updated May 05, 2026 · Updated 22 times
Summary
This early-stage study tested an experimental oral drug, SAR441566, in 38 adults with mild to moderate psoriasis. The main goal was to check safety and tolerability over 4 weeks, while also measuring how well it reduced skin symptoms like scaling and redness. Participants were randomly assigned to receive either the drug or a placebo, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PSORIASIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Investigational Site Number :2760001
Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.